Unity Biotechnology Inc (NASDAQ: UBX)’s stock price has gone rise by 16.76 in comparison to its previous close of 1.79, however, the company has experienced a 22.22% increase in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, Federico Grossi, UNITY’s Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
Is It Worth Investing in Unity Biotechnology Inc (NASDAQ: UBX) Right Now?
The stock has a 36-month beta value of 0.88. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UBX is 15.37M, and at present, short sellers hold a 1.59% of that float. On January 23, 2025, the average trading volume of UBX was 154.35K shares.
UBX’s Market Performance
UBX’s stock has seen a 22.22% increase for the week, with a 109.00% rise in the past month and a 49.29% gain in the past quarter. The volatility ratio for the week is 10.61%, and the volatility levels for the past 30 days are at 13.68% for Unity Biotechnology Inc The simple moving average for the past 20 days is 46.77% for UBX’s stock, with a 47.04% simple moving average for the past 200 days.
Analysts’ Opinion of UBX
Many brokerage firms have already submitted their reports for UBX stocks, with Rodman & Renshaw repeating the rating for UBX by listing it as a “Buy.” The predicted price for UBX in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on August 22, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see UBX reach a price target of $4, previously predicting the price at $2. The rating they have provided for UBX stocks is “Outperform” according to the report published on November 16th, 2023.
UBX Trading at 64.51% from the 50-Day Moving Average
After a stumble in the market that brought UBX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 3.47% of gains for the given period.
Volatility was left at 13.68%, however, over the last 30 days, the volatility rate increased by 10.61%, as shares surge +115.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +81.74% upper at present.
During the last 5 trading sessions, UBX rose by +22.22%, which changed the moving average for the period of 200-days by +33.12% in comparison to the 20-day moving average, which settled at $1.4200. In addition, Unity Biotechnology Inc saw 114.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UBX starting from Ghosh Anirvan, who sale 432 shares at the price of $1.29 back on Nov 04 ’24. After this action, Ghosh Anirvan now owns 75,893 shares of Unity Biotechnology Inc, valued at $557 using the latest closing price.
Sullivan Lynne Marie, the CFO & Head of Corp. Dev. of Unity Biotechnology Inc, sale 136 shares at $1.29 during a trade that took place back on Nov 04 ’24, which means that Sullivan Lynne Marie is holding 55,925 shares at $175 based on the most recent closing price.
Stock Fundamentals for UBX
Current profitability levels for the company are sitting at:
- -17.22 for the present operating margin
- 0.53 for the gross margin
The net margin for Unity Biotechnology Inc stands at -11.51. The total capital return value is set at -0.85. Equity return is now at value -86.95, with -37.61 for asset returns.
Based on Unity Biotechnology Inc (UBX), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at 1.46. The interest coverage ratio of the stock is -32757.0.
Currently, EBITDA for the company is -37.28 million with net debt to EBITDA at -0.56. When we switch over and look at the enterprise to sales, we see a ratio of 24.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.45.
Conclusion
To sum up, Unity Biotechnology Inc (UBX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
